CN113423709A - 三嗪酮并咪唑类化合物及其医药用途 - Google Patents

三嗪酮并咪唑类化合物及其医药用途 Download PDF

Info

Publication number
CN113423709A
CN113423709A CN202080014151.6A CN202080014151A CN113423709A CN 113423709 A CN113423709 A CN 113423709A CN 202080014151 A CN202080014151 A CN 202080014151A CN 113423709 A CN113423709 A CN 113423709A
Authority
CN
China
Prior art keywords
membered
aryl
cycloalkyl
alkyl
heterocyclic group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080014151.6A
Other languages
English (en)
Other versions
CN113423709B (zh
Inventor
陈寿军
宋帅
蒋小玲
唐祖建
田强
宋宏梅
薛彤彤
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN113423709A publication Critical patent/CN113423709A/zh
Application granted granted Critical
Publication of CN113423709B publication Critical patent/CN113423709B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

本发明属于医药领域，具体涉及式I所示的化合物、其可药用盐、酯、溶剂化物、立体异构体、互变异构体、前药、任意晶型、代谢物或它们的混合物。本发明还涉及式I所示的化合物、其可药用盐、酯、溶剂化物、立体异构体、互变异构体、前药、任意晶型、代谢物或它们的混合物的医药用途。本发明化合物对去泛素化酶USP7的活性具有较强抑制作用，具有良好的药代动力学性质，能用于预防或治疗癌症疾病。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN202080014151.6A 2019-04-11 2020-04-03 三嗪酮并咪唑类化合物及其医药用途 Active CN113423709B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910289078 2019-04-11
CN2019102890782 2019-04-11
PCT/CN2020/083270 WO2020207352A1 (zh) 2019-04-11 2020-04-03 三嗪酮并咪唑类化合物及其医药用途

Publications (2)

Publication Number Publication Date
CN113423709A true CN113423709A (zh) 2021-09-21
CN113423709B CN113423709B (zh) 2024-02-09

Family

ID=72750990

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080014151.6A Active CN113423709B (zh) 2019-04-11 2020-04-03 三嗪酮并咪唑类化合物及其医药用途

Country Status (2)

Country Link
CN (1) CN113423709B (zh)
WO (1) WO2020207352A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016109480A1 (en) * 2014-12-30 2016-07-07 Forma Therapeutics, Inc. Pyrrolotriazinone and imidazotriazinone derivatives as ubiquitin-specific protease 7 (usp7) inhibitors for the treatment of cancer
WO2016126935A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
CN107406451A (zh) * 2014-12-30 2017-11-28 福马治疗股份有限公司 作为泛素特异性蛋白酶7抑制剂的吡咯并嘧啶和吡唑并嘧啶
WO2018073602A1 (en) * 2016-10-20 2018-04-26 Almac Discovery Limited Piperidine derivatives as inhibitors of ubiquitin specific protease 7

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016109480A1 (en) * 2014-12-30 2016-07-07 Forma Therapeutics, Inc. Pyrrolotriazinone and imidazotriazinone derivatives as ubiquitin-specific protease 7 (usp7) inhibitors for the treatment of cancer
CN107406451A (zh) * 2014-12-30 2017-11-28 福马治疗股份有限公司 作为泛素特异性蛋白酶7抑制剂的吡咯并嘧啶和吡唑并嘧啶
WO2016126935A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2018073602A1 (en) * 2016-10-20 2018-04-26 Almac Discovery Limited Piperidine derivatives as inhibitors of ubiquitin specific protease 7

Also Published As

Publication number Publication date
WO2020207352A1 (zh) 2020-10-15
CN113423709B (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
CN109475531B (zh) Ptpn11的杂环抑制剂
CN113365988B (zh) Shp2抑制剂及其应用
CN109803972B (zh) 1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
CN109219604B (zh) 四氢异喹啉雌激素受体调节剂及其用途
EP2964223B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CA3079617A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
WO2015196071A9 (en) Compounds, compositions and methods of increasing cftr activity
AU2015266453C1 (en) Alk kinase inhibitor, and preparation method and use thereof
CA3120514A1 (en) Cyclic ureas
CN111094288A (zh) 具有mgat-2抑制活性的稠合环衍生物
JP2023541612A (ja) Ｅｇｆｒ突然変異癌の抑制用化合物及びその医薬用途
CN111655682A (zh) 一种高活性sting蛋白激动剂化合物
WO2020182018A1 (zh) 氮杂环化合物、其制备方法及用途
CN112236416A (zh) 嘧啶环己烯基糖皮质激素受体调节剂
CA2079548C (en) Carbamate derivatives of 4-amino-3- isoxazolidinones, 3-amino-1- hydroxypyrrolidin-2-ones and 1-amino-1- cyclopropanecarboxylic acid analogs, a process for their preparation and their use as medicaments
WO2021060453A1 (ja) 架橋型光学活性２級アミン誘導体
CN116262741A (zh) 作为突变型egfr抑制剂的化合物
CN111630058B (zh) 吡喃葡萄糖基衍生物及其用途
CN112654605B (zh) 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
CN113493453B (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN113423709A (zh) 三嗪酮并咪唑类化合物及其医药用途
JP2009517483A (ja) 一酸化窒素シンターゼの二量化の抑制剤としてのイミダゾール誘導体
CN113087718A (zh) 噻吩并嘧啶酮类化合物及其医药应用
CN114401722A (zh) 酪氨酸激酶的抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant